Save up to 90% on Emtricitabine/Tenofovir with Coupons, Discount Cards & Patient Assistance Programs

Emtricitabine/Tenofovir is available as an oral tablet contaning 200 mg/300 mg, 167 mg/250 mg, 133 mg/200 mg, and 100 mg/150 mg of emtricitabine and tenofovir disoproxil fumarate, respectively.

Emtricitabine/Tenofovir is a combination of 2 antivirals that are used for the following:

• Treatment of HIV infection
• Prevention of HIV infection (PrEP or pre-exposure prophylaxis)

Emtricitabine/Tenofovir is a combination of two HIV antiretroviral medications: emtricitabine and tenofovir disoproxil fumarate. Both medications are nucleoside reverse transcriptase inhibitors (NRTIs). They insert themselves into the genetic material of the virus. As a result, Emtricitabine/Tenofovir prevents HIV from making copies of itself and spreading.

Emtricitabine/Tenofovir is dosed as follows:

• Treatment of HIV – Adults and children who weigh at least 77 pounds: The typical dose is 1 tablet by mouth once daily. Each tablet contains 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate
• Children who weigh 61 to 76 pounds: The typical dose is 167 mg/250 mg (Emtricitabine/Tenofovir disoproxil fumarate) by mouth once daily.
• Children who weigh 48 to 60 pounds: The typical dose is 133 mg/200 mg (Emtricitabine/Tenofovir disoproxil fumarate) by mouth once daily
• Children who weigh 37 to 47 pounds: The typical dose is 100 mg/150 mg (Emtricitabine/Tenofovir disoproxil fumarate) by mouth once daily
• Prevention of HIV (PrEP) – Adults and children who weigh at least 77 pounds: The typical dose is 1 tablet by mouth once daily. Each tablet contains 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate.

Your dose might differ if you have kidney problems.

Emtricitabine/Tenofovir is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. If you have any of the following conditions or if any of the following apply to you, let your healthcare provider know because Emtricitabine/Tenofovir will not be safe for you to take. For HIV PrEP: People who have HIV (tested positive for HIV) or aren’t sure what their HIV status is

Common side effects of Emtricitabine/Tenofovir:

• Higher cholesterol levels
• Higher creatine kinase levels
• Feeling tired
• Depression
• Nausea
• Diarrhea
• Dizziness
• Upper respiratory infections
• Sinus infection
• Rash
• Headache
• Belly pain
• Lower weight

Serious side effects are rare with Emtricitabine/Tenofovir. Contact your healthcare provider immediately if you experience any of the following.

• Buildup of lactic acid in the blood (lactic acidosis): feeling more tired and weak, belly pain, muscle pain, breathing problems
• Kidney problems: tiredness; confusion; nausea; urinating less than usual; swelling in your legs, ankles, or feet; joint or bone pain
• Liver problems: nausea, vomiting, not feeling hungry, pain in the right side of the stomach, yellowing of the whites of the eyes or skin, dark-colored urine, light-colored stool
• Bone fracture

The following medications may interact with Emtricitabine/Tenofovir:

• Emtricitabine/Tenofovir increases didanosine concentrations
• Dose reduction and close monitoring for didanosine toxicity are warranted
• Coadministration decreases atazanavir concentrations. When
• coadministered with Emtricitabine/Tenofovir, use atazanavir given with ritonavir
• Coadministration of Emtricitabine/Tenofovir with certain HIV-1 protease inhibitors or certain drugs to treat HCV increases tenofovir concentrations
• Monitor for evidence of tenofovir toxicity
• Consult Full Prescribing Information prior to and during treatment for important drug interactions

Various FDA-approved generic manufacturers

Data on the use of Emtricitabine/Tenofovir during pregnancy from observational studies have shown no increased risk of major birth defects. However, you should talk to your doctor before taking Emtricitabine/Tenofovir if you are pregnant. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Emtricitabine/Tenofovir during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263

• Truvada